Member Info for Scinv_temp

Sure. I just hope they have enough for phase 3 if the results are supportive.

Yay!

Yes they may have reduced the size and data they could extract in order to do another small trial in which they still did not have enough for the people who run it to do it the way the wanted to. Around the same period when they were sorting this out, they were promising 100K treatments per month from Jan 2021.

How is this good in any way?

The more private the group of random private gamblers you get your info from, the higher the share price will be for you. Lol

And the truth is that is has been there for a while.

Here is a snapshot from August 2020
http://web.archive.org/web/20200831023318/https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html

What exactly was your function in the industry? Also look at all these topical cancer drugs. Lol. This may apply to radiation techniques, some treatments that are combined with invasive procedures (ie to clamp arteries so the the drug concentrates on a specific part of the body) and some forms of immunotherapy esp in skin cancers but that's simply because it is more convenient.
The aim is always selectivity to cancer cells with a strong rationale of mechanism of action.

It is unethical, and illegal, to allude to be an expert in a medical field. So what was your function in the pharmaceutical industry?

And it's absorption by the way, adsorption is something very different, an example is peptides in a vaccine adsorbed on aluminium nanoparticles

Saying that this is certain is disingenuous and you know it. And then decorated by the usual filth of this board. By the way I love gardening and I love nature.

The science is supportive but that does not mean it is certain.

1. Maybe IFN is most beneficial in cases where covid-induced exarcebation are due to defects of ifn signalling upstream of the receptor (for example auto antibodies or inability of the cell to produce enough quantity of the ligand in response to the virus). This it seems to be the case in about 20% of the hospitilised cases. Do we know what happens with the rest? This isn't a certainty. This all still being investigated. Do we know if there are deficiences downstream of the receptor as well (and therefore doesn't matter if the ligand is there or not)?

2. Do we know FOR SURE that sng can deliver quantities in relevant timeframes?

3. Do we know for sure, that other will not come up with similar solutions and better pricing by repurposing and existing approved ifnb drug? Even if you think it is certain that no one else can have another inhaled IFNb formulation (imo this is FAR from certain), do we know if the presence of the antibodies can be overcome by simply using higher concentration of IFNa, this is isn't an on off switch, it is concentration dependent, both of the autoantibodies and the ligand.

No man. WE DON'T.

No man. I'll stick around if you want to, though if some great news arrives I will most likely sell the rest of my shares shortly after. Will you and the other Mikes stick around if things go south?

And I can't understand someone who is a shareholder but choses to ignore relevant information. The things I point out are the reason I heavily reduced my position. Risk management, you know? Stuff that investors do, yeah? Do you understand now Mike?

Yeah he said in the same response that the virus needs to replicate, except that happens from earpy on and if you knew anything about treatments, if you were to target something that replicates it best caught before it actually takes over a tissue. So he contradicted himself. And it wasn't the first time. Maybe look the expressions of the host and the invited analyst.aybe that will tell you something so here's hoping.

Standard of care actually includes a multitude of drugs, despite remdesivir (at least in part for pr reasons), dexamethasone and the monoclonal coctails getting most of the spotlight.

Mike cut the bs. There is a mutlitude of occasions where govs commited to buy PENDING results. This has not happened with SNG. And EUA means there is at least a meaningful quantity ready to go, otherwise it makes no sense to give EMERGENCY authorisation. It is the company's risk to take and in any case I would perhaps understand that if they did not communicatr something very different last year.

Yet I see RM downplaying the home trial (it will be a lot weirder if HT actually delivers v good results), TW talking about the possible plans to do trials in patients in icu, RM again talking about antibody responses when they could simply sort that out by ACTUALLY checking, SH "we know it works" when this does not make sense without the actual results, talking about "15 years of safety data" when in in fact no more than 300 pstients had received the drug OR placebo at the time it was said amdnwith a maximum follow up of one year. I'm not going to repeat the allusions about manufacturing and availability vs not enough for the receuitment sites of trials or an additional lower dose which even if it wasn't as good it would still be very helpful because scientists LOVE a dose response as it increases confidence. Allowing a price a to leak with a popular communicator without intervening IMMEDIATELY to at least say this is inaccurate and much later talking about very different pricing which later they dropped. This is not even an exhaustive list.

So no Ghia. No. They need to know that we actually pay attention. And investros should understand the risks. I still keep my heavily reduced position, since I still maintain some hope that we will something from at least one of the ongoing trials. But I can't ignore everything else.

Yes no one bothered to commit to buy anything from sng because they are all evil, the UK, the US, everyonre. It never crossed your mind that maybe they simply don't trust the company to deliver. The narrative that sng is somehow work8ng with operation warp speed and that orders are guaranteed or that any deals are in place are false. OWS (which doesn't even exist anymore but anyway let's say their role has been assumed in full by the new covid response team) is funding the activ platform. Just because the drug was accepted on the platform that doesn't mean there are other deals in place. If you check every other case where manufacturing and or pre-orders were supported by OWS this was announced specifically, either separately from clinical trials or in a different section of the same communication that talks about tue particulars of pre-orders and/or manufacturing support.
This has not happened for SNG. Nor has OWS supported trials AND manufacturing in all cases. This is a fact.

So maybe sng the company simply has not convinced anyone yet that they can be the real deal as opposed to the possibility that everyone is evil and RM the knight in shinning armor who wants to save the world.

My personal "favourite" was when they kept banging about how much Fauci loves sng001 while sharing comments of him talking about direct anti virals soecifically, therefore excluding ifns in those comments.

It wouldn't be the first time that the most "deramping" comments come from the pumpers themselves. It is ridiculous really and has been for some time now

More spocifically, for example rebif is the approved drug but sng001 is not, giving it by inhalation is the repurposing part of an approved drug.

It isn't that straightforward. It isn't straightforward at all. If they are going for an anti-imflammatory mechanism then we will some animal studies published or at least communicated via other means with sng001 and late stage covid in those animal models that at least points to a specific mechanism.

Otherwise, it seems that patients on oxygen are back in focus in the narrative and anyway that is whar they are testing in phase 3.